Posts by: Alice Melão

Alice Melão

September 11, 2018

Adcetris-Chemotherapy Combo Improves Survival Rates in Elderly Hodgkin’s Patients, Phase 2 Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly improves responses and survival rates of elderly patients with newly diagnosed Hodgkin’s lymphoma, a Phase 2 study shows. In the trial, 90% of ... Read more

July 24, 2018

CLR 131 Significantly Reduces DLBCL Patients’ Tumor Size in Phase 2 Trial

News

The investigative drug CLR 131 all but eliminated tumor cells in one-third of diffuse large B-cell lymphoma (DLBCL) patients treated in a Phase 2 trial, and is showing promise in other kinds ... Read more

July 20, 2018

Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows

News

Adding Imbruvica (ibrutinib) to a standard chemotherapy regimen does not improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL), a Phase 3 trial ... Read more

July 17, 2018

FDA OKs Adagene’s ADG-106 for Clinical Trial in Solid Tumors, Non-Hodgkin’s Lymphoma

News

Adagene soon will initiate a Phase 1 clinical trial testing its lead product, ADG-106, in patients who have advanced solid tumors and non-Hodgkin’s lymphoma, the company announced. This follows the U.S. ... Read more

July 11, 2018July 11, 2018

Health Canada OKs Gazyva as First-line Therapy for Advanced Follicular Lymphoma

News

Patients in Canada who have advanced follicular lymphoma now can receive Gazyva (obinutuzumab) in combination with chemotherapy as first-line therapy, Roche Canada announced. Health Canada’s decision follows Gazyva’s approval in the ... Read more

July 3, 2018

FDA Names CPI-613, Potential Treatment for Burkitt’s Lymphoma, an Orphan Drug

News

The U.S. Food and Drug Administration has again designated Rafael Pharmaceuticals’ lead candidate CPI-613 an orphan drug, this time to further advance it in clinical trials as a potential treatment for Burkitt’s lymphoma. ... Read more

June 21, 2018

HDAC6 Inhibitor QTX125 Slows Mantle Cell Lymphoma Progression, Preclinical Study Shows

News

A new epigenetic therapy that prevents DNA modifications is able to slow down the growth of mantle cell lymphoma and induce cancer cell death, a study in mice and lab-grown ... Read more

June 8, 2018

Imbruvica-Rituxan Combo Significantly Delays Progression of Rare Type of Lymphoma in Phase 3 Trial

News

A combination of Imbruvica (ibrutinib) and Rituxan (rituximab) significantly extends the time to disease worsening or death in patients with a rare type of lymphoma called Waldenström’s macroglobulinemia, a Phase 3 trial ... Read more

June 5, 2018

Phase 2 Data Continues to Support Remetinostat in Easing Itching in Early Stage Mycosis Fungoides

News

Topical remetinostat gel significantly reduces itching in patients with a kind of cutaneous T-cell lymphoma called mycosis fungoides, data from a Phase 2 trial shows. The medicine also reduced the ... Read more

June 4, 2018

Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors

News

Alexo Therapeutics has started treating patients in the combination part of its Phase 1 trial, which will test multiple combinations of ALX148 with targeted antibody therapies — including Keytruda (pembrolizumab), Herceptin ... Read more